Neuro-ischemic Ulcers Segment to Dominate Europe Diabetic Foot Ulcer Treatment Market During 2021–2028     

According to a new market research study on “Europe Diabetic Foot Ulcer Treatment Market to 2028 – COVID-19 Impact and Regional Analysis and Forecast by Type, Ulcer Type, and End User” is expected to reach US$ 2,011.59 million by 2028 from US$ 1,213.31 million in 2021. The market is estimated to grow at a CAGR of 7.5% from 2021 to 2028. The report provides trends prevailing in the Europe diabetic foot ulcer treatment market along with the drivers and restraints pertaining to the market growth. Rising geriatric population and increasing prevalence of diabetes and related chronic wounds are the major factor driving the growth of the Europe diabetic foot ulcer treatment market. However, expensive advanced wound care treatments hinders the growth of Europe diabetic foot ulcer treatment market.  

In case of COVID-19, Europe is highly affected specially France. Short-term impacts of the COVID-19 pandemic include demand changes, revision in the regulatory process, changes in the research and development process, and the shift towards telecommunication and telemedicine. Moreover, the slowdown in market growth, delay in product approval, adoption of the self-sufficient pharm-production supply chain, and changes in the trend in consumption of health-market products and ethical dilemmas could be anticipated as long-term impacts of the COVID-19 pandemic on the pharmaceutical sector in both global and local levels. Various companies have undergone severe losses in the last quarter of 2019 and have negatively impacted the year 2020. As to control the spread of disease, countries have imposed complete lockdown. The lockdown has resulted in slower economies due to closed trades and business. Lockdown in France has caused delays in the raw material used for wound care products. However, companies like Molnlycke has reported 2.1% growth in their wound care sales. Company has utilized telehealth solution practices by providing education to professionals and clinicians in this business. The diabetic foot ulcer treatment market in Europe is expected to present steady growth post pandemic period. As the vaccination drives progress the healthcare system in Europe will get normalized and start focusing on wound care practices. This is expected to gradually increase the demand for diabetic foot ulcer products in Europe.

The Europe diabetic foot ulcer treatment market is segmented based on the type, ulcer type, end user, and country. Based on type, the market has been segmented into the advanced wound care dressings, biologics, and therapy device. The advanced wound care dressings segment dominated the Europe diabetic foot ulcer treatment market in 2020 and biologics segment is expected to be fastest growing during forecast. Further, advanced wound care dressings is segmented into hydrogel dressings, collagen dressing, alginate dressings, foam dressings, hydrocolloid dressings, and others. Further, biologics is segmented into the skin grafts and growth factors. Similarly, therapy device is segmented into negative pressure wound therapy and ultrasound therapy. Based on ulcer type, the market has been segmented into neuropathic ulcers, ischemic ulcers, and neuro-ischemic ulcers. The neuro-ischemic ulcers segment dominated the Europe diabetic foot ulcer treatment market in 2020 and same segment is expected to be fastest growing during forecast. Moreover, based on end user, the market has been segmented into the hospitals, ambulatory surgery centers, and home care. The hospital segment dominated the Europe diabetic foot ulcer treatment market in 2020 and same segment is expected to be fastest growing during forecast. Based on country, the market has been segmented into the UK, Germany, France, Italy, Spain, and rest of Europe. 

3M; B. Braun Melsungen AG; Cardinal Health Inc; Coloplast Group; ConvaTec Group Plc; Kerecis; Medline Industries, Inc.; MiMedx; Mölnlycke Health Care AB.; Organogenesis Inc.; Smith & Nephew; and URGO are among the leading companies in the Europe diabetic foot ulcer treatment market. The companies are focused on adopting organic growth strategies such as product launches and expansions to sustain their position in the dynamic market. For instance, in 2019, 3M has completed acquisition of Acelity, Inc. and its KCI subsidiaries worldwide. Acelity is a leading global medical technology company focused on advanced wound care and specialty surgical applications marketed under the KCI brand. This acquisition has further accelerated 3M's position as a leader in advanced wound care market.      

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com